Autophagic Flux

Flux is the word that matters. Autophagy is not a single event but a throughput — cargo captured, delivered, degraded, and the products returned — and measuring any one step tells you nothing about whether the pathway is working. A cell can be inducing autophagy vigorously and clearing nothing.

That distinction is why this corpus treats flux rather than autophagy as the concept of interest, and it is the source of its sharpest therapeutic warning.

The blockage, not the brake

In the Alzheimer neuron the defect is at the disposal end. Vacuoles are captured and delivered normally; they are not degraded, because the lysosome cannot acidify. The morphological result is the PANTHOS neuron — engorged with undigested autophagic vacuoles — and the corpus reads the plaque as what such a neuron leaves behind.

The therapeutic consequence follows immediately and inverts the intuitive move: re-acidify before you induce. An autophagy inducer given to a cell whose lysosomes cannot digest increases the load on a blocked pipe. Several agents in the field's pipeline are inducers, which is why the corpus grades this ordering constraint as clinically load-bearing rather than academic.

The immune route to the same pump

Greenblatt's submission (66) reaches autophagic flux from an unexpected direction: BCG vaccination and trained innate immunity. The proposed chain is that a systemic metabolic shift toward aerobic glycolysis recruits Aldolase A to scaffold v-ATPase reassembly on lysosomal membranes, restoring acidification and therefore flux — with LL-37 and vitamin D pathways contributing direct anti-amyloid and immunomodulatory effects alongside.

What makes this interesting to the corpus is not the vaccine but the mechanism's shape: a glycolytic enzyme moonlighting as a structural scaffold for the proton pump. It connects energy metabolism to lysosomal function through a physical interaction rather than through a general appeal to "metabolic fitness" — precisely the kind of specification the trilogy's own audit found missing.

Other levers on flux

• TFEB activators, driving the transcriptional programme for lysosomal biogenesis and renewal.
• TRPML1 agonists, promoting lysosomal calcium signalling and downstream biogenesis — relevant because at least one PSEN-related lysosomal defect turns out to be a calcium defect rather than a pump defect.
• Gamma entrainment, argued to resuscitate the autophagy–lysosome pathway bioenergetically rather than pharmacologically.

Related

Lysosomal Dysfunction · Autophagy Dysfunction · Proteostasis · Energy Metabolism · Trained Immunity · Endolysosomal Dysfunction · Endosomal Nexus